# Expression of LGR5, FZD7, TROY, and MIST1 in Perioperatively Treated Gastric Carcinomas and Correlation with Therapy Response

Authors: Antonia Freiin Grote; Christine Halske; Hans-Michael Behrens; Sandra Krüger; Franziska Wilhelm; Jan-Hendrik Egberts; Christoph Röcken
Journal: Disease Markers
 (2019)

---

## Abstract

The cancer stem cell model is considered as a putative cause of resistance to chemotherapy and disease recurrence in malignant tumors. In this study, we tested the hypothesis that the response to neoadjuvant/perioperative chemotherapy correlates with the expression of four different putative cancer stem cell markers of gastric cancer (GC), i.e., LGR5, FZD7, TROY, and MIST1. The expression of LGR5, FZD7, TROY, and MIST1 was assessed by immunohistochemistry in 119 perioperatively treated GCs including pretherapeutic biopsies, resected primary GCs, and corresponding nodal and distant metastases. All four markers were detected in our cohort with variable prevalence and histoanatomical distributions. Few tumor cells expressed TROY. LGR5, FZD7, and MIST1 were coexpressed in 41.2% and completely absent in 6.2%. The prevalence of LGR5- and FZD7-positive GCs was higher and of TROY-positive GCs lower in perioperatively treated GCs compared with treatment-naïve tumors. LGR5, FZD7, and MIST1 in the primary tumors correlated significantly with their expression in the corresponding lymph node metastasis. An increased expression of LGR5 in primary GC correlated significantly with tumor regression. The expression of MIST1 in lymph node metastases correlated significantly with the number of lymph node metastases as well as overall and tumor-specific survival. FZD7 did not correlate with any clinicopathological patient characteristic. Our study on clinical patient samples shows that GCs may coexpress independently different stem cell markers; that neoadjuvant/perioperative treatment of GC significantly impacts on the expression of stem cell markers, which cannot be predicted by the analysis of pretherapeutic biopsies; and that their expression and tumor biological effect are heterogeneous and have to be viewed as a function of histoanatomical distribution.


---

## Body

## 1. Introduction

Gastric cancer (GC) is a leading cause of cancer death worldwide [1]. In Western countries, GC is often diagnosed at an advanced stage, leading to an overall poor prognosis [2]. Several studies have shown that patients with limited metastatic disease benefit from neoadjuvant/perioperative chemotherapy [3–5]. However, therapy response is unpredictable, and complete (Becker regression grade 1a) or subtotal (Becker regression grade 1b) response is achieved only in less than 30% of the patients [6].The tumor stem cell hypothesis assumes that chemotherapy leads to a selective survival of resistant cancer stem cells (CSC), which are protected by different mechanisms from the effects of chemotherapy [7]. CSCs are then able to initiate tumor regrowth leading to tumor recurrence [7]. The resistance of CSCs to conventional chemotherapeutic agents has been demonstrated in a large number of studies [8–10], raising hopes that CSCs may serve as predictive or prognostic markers of therapeutic efficacy. However, evidence in clinical samples is scarce often due to the lack of appropriate biomarkers to screen for CSCs in tissue samples. With regard to GC, four different molecules had been suggested to be CSC markers.The G-protein-coupled receptor LGR5 (leucine-rich repeat-containing G-protein-coupled receptor 5) is a target gene of the WNT signaling pathway, which can lead to an amplification of the WNT/β-catenin signal via the binding of R-spondins [11, 12]. LGR5 is a marker of adult stem cells of the stomach, the hair follicles, the small intestine, and the colon [13–15]. Several studies have already shown an association between LGR5 expression in GC and increased tumor progression, metastasis, and worse prognosis [16, 17]. LGR5 has also been implicated in the chemotherapy resistance of various cancers, as well as in GC [18–21].FZD7 (Frizzled-7) is another target gene of the WNT signaling pathway that can activate the WNT signaling pathway in the presence of the coreceptor LRP [22, 23]. It was shown that FZD7 is involved in the maintenance of stem cell activity in embryonic stem cells [24]. FZD7 is vital for tissue homeostasis in the gastric epithelium: deletion of FZD7 in the mouse model leads to a dramatic reduction of mucus-secreting cells. FZD7 may regulate Muc5a expression and thus the differentiation of mucus-secreting cells. Deletion of FZD7 also leads to gastric repopulation [25]. In GC, upregulation of FZD7 was detected and associated with tumor progression, metastasis, and poor prognosis [26–28]. Recently, it was shown that FZD7 is the predominant Wnt receptor responsible for transmitting Wnt signaling in gastric tumor cells and plays an essential role in tumorigenesis [29]. Li et al. described FZD7 as an important factor in the CSC activity of GC [27]. Apart from GC, dysregulation of FZD7 was also observed in, e.g., colon, hepatocellular, and breast cancers [30–32]. For hepatocellular carcinoma and squamous cell carcinoma of the esophagus, an association between FZD7 expression and lack of response has been shown [33, 34]. FZD7 also regulates the function of LGR5 stem cells in the intestine [35].TROY (tumor necrosis factor receptor superfamily, member 19), also a target gene of the WNT signaling pathway, causes negative feedback and thus indirect inhibition of the signaling pathway [36, 37]. TROY is important in the development of hair follicles and embryonic skin [38, 39]. Furthermore, in the stomach, a group of TROY expressing chief and parietal cells are present at the gland base of the corpus, of which the TROY expressing chief cells had abilities of self-contained reserve stem cells [37, 40]. In addition, dysregulation of TROY was observed in malignant melanoma, glioblastoma, and GC [37, 41, 42]. There was a significantly more frequent expression of TROY in GC in well to moderately differentiated tumors, intestinal carcinomas, and tumors without lymph node metastases [37]. Moreover, patients with a lack of TROY expression had a worse prognosis [37].MIST1 (muscle, intestine, and stomach expression 1/BHLHA15) is a transcription factor belonging to the family of bHLH proteins [43]. It is involved in the development of the exocrine pancreas, liver, and stomach [43–45]. In the adult murine stomach, Hayakawa et al. found a slowly dividing subpopulation of MIST1-positive isthmus cells of the corpus gland, which could represent the origin of all cell lines in the corpus epithelium by bidirectional migration [46]. However, differentiated zymogenic chief cells at the base of the corpus glands did not show any stem cell properties [46]. In addition, they showed that the MIST1-positive isthmus cells can be the starting point of intestinal and diffuse GC [46]. Moreover, in the isthmus area of the antrum, a group of long-lived MIST1-positive progenitor cells were found, which were largely independent of other stem cell populations and can serve as an origin of antral tumors [47].In this study, we tested the hypothesis that the response to neoadjuvant/perioperative chemotherapy correlates with the expression of four different CSC markers of GC, i.e., LGR5, FZD7, TROY, and MIST1 by using clinical samples.


## 2. Materials and Methods

### 2.1. Ethics Statement

The study was approved by the local ethical review board (D 525/15). All patient data were pseudonymized.


### 2.2. Study Population

From the archive of the Institute of Pathology, University Hospital Kiel, we sought all patients who had undergone either total or partial gastrectomy for adenocarcinoma of the stomach or esophagogastric junction between 1998 and 2016. The following patient characteristics were retrieved: type of surgery, age at diagnosis, gender, tumor size, tumor localization, tumor type, depth of invasion, number of lymph nodes resected, and number of lymph nodes with metastases [48]. Patients were included if an adenocarcinoma of the stomach or esophagogastric junction was histologically confirmed and the patients had undergone neoadjuvant or perioperative chemotherapy. Exclusion criteria were defined as follows: (1) histology identified a tumor type other than adenocarcinoma and (2) patients had not received a perioperative or neoadjuvant chemo- or radiotherapy. Each resected specimen had undergone gross sectioning and histological examination by trained and board-certified surgical pathologists. Date of patient death was obtained from the Epidemiological Cancer Registry of the state of Schleswig-Holstein, Germany. Follow-up data of those patients who were still alive were retrieved from hospital records and general practitioners [48]. Of all included patient cases, the pretherapeutic biopsy, primary tumor, lymph node metastasis, and distant metastasis were examined, if available.


### 2.3. Histology

Tissue samples were fixed in formalin and embedded in paraffin. Subsequently, all deparaffinized sections were stained with hematoxylin and eosin (H&E). Histological reexamination of primary tissue sections was carried out for all cases to assure if inclusion criteria were met. Tumors were classified according to the Laurén classification [49] and reexamined by two surgical pathologists. The pTNM stage of all study patients was determined according to the 7th edition of the UICC guidelines [48, 50]. To assess the response to therapy, the amount of tumor residuals with respect to the chemotherapeutic scar was estimated in percentage on the primary tumor sections. Based on this quantitative assessment, all patient cases were divided into two (divided by the median) and four groups (divided into quartiles). In addition, the Becker regression score was determined for each case [51, 52].


### 2.4. Immunhistochemistry

Immunohistochemistry was performed on formalin-fixed and paraffin-embedded sections using antibodies directed against FZD7 (polyclonal, rabbit, Abcam, Cambridge, USA, ab51049, 1 : 200), LGR5 (polyclonal, rabbit, Pineda, Berlin, Germany, not commercial, 1 : 1000), TROY (monoclonal, clone EPR3213(2), rabbit, Abcam, Cambridge, USA, ab138502, 1 : 2000), and MIST1 (monoclonal, clone D7N4B, rabbit, Cell Signaling Technology, Danvers, USA, #14896, 1 : 100). The Leica BOND MAX (Leica Biosystems, Nußloch, Germany) was used for immunostaining of LGR5, TROY, and MIST1 using the BOND polymer refine detection kit (Leica Biosystems, Nußloch, Germany). For MIST1 and TROY immunostaining, deparaffinized tissue sections were pretreated for 20 min with ER2-antigen retrieval solution (Leica Biosystems, Nußloch, Germany).Immunostaining of FZD7 was done manually. In brief: following antigen retrieval in citrate buffer (125°C), tissue sections were incubated with lab vision hydrogen peroxide block and ultra v block (both Thermo Fisher Scientific GmbH, Schwerte, Germany) in order to avoid unspecific background. Incubation with the primary antibody was done for 30 minutes at room temperature and subsequently overnight at 4°C. Immunoreactions were visualized with the ImmPRESS HRP Universal Antibody and ImmPact NovaRed Peroxidase Substrate (both Vector Laboratories, Burlingame, USA). Between the steps, all slides were washed with Tris-buffered saline (TBS). For counterstaining, hematoxylin (Dr. K. Hollborn & Söhne GmbH & Co. KG, Leipzig, Germany) was used. Immunohistochemical stainings were validated by reverse transcriptase reaction and quantitative real-time PCR (qRT-PCR) on a selected number of cases (Supplementary FileS1).


### 2.5. Evaluation of Immunostaining

Immunostaining of tumor cells was evaluated according to a modified immunoreactivity scoring system (IRS): Category A documented the maximum intensity of the positive tumor cells as absent (0), weak (1), moderate (2), and strong (3). Category B documented the percentage of positive tumor cells in a marker-specific approach into four grades, i.e., negative (LGR5: 0% positive tumor cells; MIST1: 0%; FZD7: 0%), 1+ (LGR5: 0.1-19% positive tumor cells; MIST1: 0.1-1%; FZD7: 0.1-1%), 2+ (LGR5: 20-49% positive tumor cells; MIST1: 2-10%; FZD7: 2-10%), and 3+ (LGR5: ≥50% positive tumor cells; MIST1: ≥11%, FZD7: ≥11%). This categorization resulted in a more homogeneous distribution of the percentage of stained tumor cells for each individual biomarker. The addition of categories A and B added up to an IRS of 0 to 6. Finally, the median IRS served as a cut-off to differentiate between low/negative and high. In addition to the IRS, we documented the location of positive tumor cells, i.e., tumor surface, tumor center, and invasion front.


### 2.6. Study Design

The study cohort consisted of 119 neoadjuvantly/perioperativley treated patients with GC. Resected primary tumor sites were available in 118 cases, of which 105 still enclosed residuals of the viable primary tumor. In a single patient, the primary tumor could not be analyzed due to technical limitations. Lymph nodes were studied from 79 patients, of which 71 had histological evidence of lymph node metastases. Selection was based on either tumor cells present in the lymph nodes (nodal positive GC) or evidence of tumor regression in lymph nodes, as sometimes, viable tumor cells were found on deeper step sections. 14 distant metastases were available from 10 GC patients, and pretherapeutic biopsies with tumor were available from 25 patients. In total, we studied 236 tissue samples for the presence of LGR5, FZD7, MIST1, and TROY. With regard to primary tumor, the tumor compartments, tumor surface, tumor center, and invasion front were assessed separately. The results were correlated with various clinicopathological patient characteristics and survival.


### 2.7. Statistical Analyses

Statistical analyses were done using SPSS version 24 (IBM, Corp., Aramark, USA). Variables of the ordinal scale were tested with Kendall’s tau test and nonordinal variables with Fisher’s exact test. Median survival with 95% confidence intervals was determined by the Kaplan-Meier method. Differences between median survivals were tested with the log rank test. Cox regression was used for multivariate analysis. In all tests, ap value ≤ 0.05 was defined as statistically significant. The multivariable analysis also included influencing factors with a p value < 0.10. The explorative Simes procedure [53] was used for each antibody separately to control the false discovery rate. All p values are marked, which remained significant after the Simes procedure.


## 2.1. Ethics Statement

The study was approved by the local ethical review board (D 525/15). All patient data were pseudonymized.


## 2.2. Study Population

From the archive of the Institute of Pathology, University Hospital Kiel, we sought all patients who had undergone either total or partial gastrectomy for adenocarcinoma of the stomach or esophagogastric junction between 1998 and 2016. The following patient characteristics were retrieved: type of surgery, age at diagnosis, gender, tumor size, tumor localization, tumor type, depth of invasion, number of lymph nodes resected, and number of lymph nodes with metastases [48]. Patients were included if an adenocarcinoma of the stomach or esophagogastric junction was histologically confirmed and the patients had undergone neoadjuvant or perioperative chemotherapy. Exclusion criteria were defined as follows: (1) histology identified a tumor type other than adenocarcinoma and (2) patients had not received a perioperative or neoadjuvant chemo- or radiotherapy. Each resected specimen had undergone gross sectioning and histological examination by trained and board-certified surgical pathologists. Date of patient death was obtained from the Epidemiological Cancer Registry of the state of Schleswig-Holstein, Germany. Follow-up data of those patients who were still alive were retrieved from hospital records and general practitioners [48]. Of all included patient cases, the pretherapeutic biopsy, primary tumor, lymph node metastasis, and distant metastasis were examined, if available.


## 2.3. Histology

Tissue samples were fixed in formalin and embedded in paraffin. Subsequently, all deparaffinized sections were stained with hematoxylin and eosin (H&E). Histological reexamination of primary tissue sections was carried out for all cases to assure if inclusion criteria were met. Tumors were classified according to the Laurén classification [49] and reexamined by two surgical pathologists. The pTNM stage of all study patients was determined according to the 7th edition of the UICC guidelines [48, 50]. To assess the response to therapy, the amount of tumor residuals with respect to the chemotherapeutic scar was estimated in percentage on the primary tumor sections. Based on this quantitative assessment, all patient cases were divided into two (divided by the median) and four groups (divided into quartiles). In addition, the Becker regression score was determined for each case [51, 52].


## 2.4. Immunhistochemistry

Immunohistochemistry was performed on formalin-fixed and paraffin-embedded sections using antibodies directed against FZD7 (polyclonal, rabbit, Abcam, Cambridge, USA, ab51049, 1 : 200), LGR5 (polyclonal, rabbit, Pineda, Berlin, Germany, not commercial, 1 : 1000), TROY (monoclonal, clone EPR3213(2), rabbit, Abcam, Cambridge, USA, ab138502, 1 : 2000), and MIST1 (monoclonal, clone D7N4B, rabbit, Cell Signaling Technology, Danvers, USA, #14896, 1 : 100). The Leica BOND MAX (Leica Biosystems, Nußloch, Germany) was used for immunostaining of LGR5, TROY, and MIST1 using the BOND polymer refine detection kit (Leica Biosystems, Nußloch, Germany). For MIST1 and TROY immunostaining, deparaffinized tissue sections were pretreated for 20 min with ER2-antigen retrieval solution (Leica Biosystems, Nußloch, Germany).Immunostaining of FZD7 was done manually. In brief: following antigen retrieval in citrate buffer (125°C), tissue sections were incubated with lab vision hydrogen peroxide block and ultra v block (both Thermo Fisher Scientific GmbH, Schwerte, Germany) in order to avoid unspecific background. Incubation with the primary antibody was done for 30 minutes at room temperature and subsequently overnight at 4°C. Immunoreactions were visualized with the ImmPRESS HRP Universal Antibody and ImmPact NovaRed Peroxidase Substrate (both Vector Laboratories, Burlingame, USA). Between the steps, all slides were washed with Tris-buffered saline (TBS). For counterstaining, hematoxylin (Dr. K. Hollborn & Söhne GmbH & Co. KG, Leipzig, Germany) was used. Immunohistochemical stainings were validated by reverse transcriptase reaction and quantitative real-time PCR (qRT-PCR) on a selected number of cases (Supplementary FileS1).


## 2.5. Evaluation of Immunostaining

Immunostaining of tumor cells was evaluated according to a modified immunoreactivity scoring system (IRS): Category A documented the maximum intensity of the positive tumor cells as absent (0), weak (1), moderate (2), and strong (3). Category B documented the percentage of positive tumor cells in a marker-specific approach into four grades, i.e., negative (LGR5: 0% positive tumor cells; MIST1: 0%; FZD7: 0%), 1+ (LGR5: 0.1-19% positive tumor cells; MIST1: 0.1-1%; FZD7: 0.1-1%), 2+ (LGR5: 20-49% positive tumor cells; MIST1: 2-10%; FZD7: 2-10%), and 3+ (LGR5: ≥50% positive tumor cells; MIST1: ≥11%, FZD7: ≥11%). This categorization resulted in a more homogeneous distribution of the percentage of stained tumor cells for each individual biomarker. The addition of categories A and B added up to an IRS of 0 to 6. Finally, the median IRS served as a cut-off to differentiate between low/negative and high. In addition to the IRS, we documented the location of positive tumor cells, i.e., tumor surface, tumor center, and invasion front.


## 2.6. Study Design

The study cohort consisted of 119 neoadjuvantly/perioperativley treated patients with GC. Resected primary tumor sites were available in 118 cases, of which 105 still enclosed residuals of the viable primary tumor. In a single patient, the primary tumor could not be analyzed due to technical limitations. Lymph nodes were studied from 79 patients, of which 71 had histological evidence of lymph node metastases. Selection was based on either tumor cells present in the lymph nodes (nodal positive GC) or evidence of tumor regression in lymph nodes, as sometimes, viable tumor cells were found on deeper step sections. 14 distant metastases were available from 10 GC patients, and pretherapeutic biopsies with tumor were available from 25 patients. In total, we studied 236 tissue samples for the presence of LGR5, FZD7, MIST1, and TROY. With regard to primary tumor, the tumor compartments, tumor surface, tumor center, and invasion front were assessed separately. The results were correlated with various clinicopathological patient characteristics and survival.


## 2.7. Statistical Analyses

Statistical analyses were done using SPSS version 24 (IBM, Corp., Aramark, USA). Variables of the ordinal scale were tested with Kendall’s tau test and nonordinal variables with Fisher’s exact test. Median survival with 95% confidence intervals was determined by the Kaplan-Meier method. Differences between median survivals were tested with the log rank test. Cox regression was used for multivariate analysis. In all tests, ap value ≤ 0.05 was defined as statistically significant. The multivariable analysis also included influencing factors with a p value < 0.10. The explorative Simes procedure [53] was used for each antibody separately to control the false discovery rate. All p values are marked, which remained significant after the Simes procedure.


## 3. Results

The characteristics of our patient cohort are summarized in Table1. A total of 119 patients fulfilled all study criteria. Survival data were available in 115 (96.6%) cases. The mean follow-up period was 29.5 months (range 0.3 to 117.9 months).Table 1
Correlation of LGR5 and MIST1 expression in primary resected gastric cancer and lymph node metastases, respectively, with clinicopathological patient characteristics.
(a)
Valid
Primary resected tumor
Lymph node metastasis
LGR5 score 0-6
MIST1 score 0-6
Low (0-4)
High (5-6)
Negative (0)
Positive (2-6)
n
(%)
n
(%)
n
(%)
n
(%)
n
(%)
Gender
n
p(1)
101
0.797
64
0.728
Male
95
(79.8)
47
(56.6)
36
(43.4)
32
(59.3)
22
(40.7)
Female
24
(20.2)
11
(61.1)
7
(38.9)
7
(70.0)
3
(30.0)
Age
n
p(1)
101
0.423
64
0.204
<64 years
60
(50.4)
31
(62.0)
19
(38.0)
24
(68.6)
11
(31.4)
≥64 years
59
(49.6)
27
(52.9)
24
(47.1)
15
(51.7)
14
(48.3)
Laurén
n
p(1)
101
0.100
64
0.951
Intestinal
52
(43.7)
30
(61.2)
19
(38.8)
17
(63.0)
10
(37.0)
Diffuse
25
(21.0)
17
(70.8)
7
(29.2)
9
(64.3)
5
(35.7)
Mixed
18
(15.1)
8
(44.4)
10
(55.6)
8
(57.1)
6
(42.9)
Unclassifiable
14
(11.8)
3
(30.0)
7
(70.0)
5
(55.6)
4
(44.4)
Complete regression
10
(8.4)
Localization
n
p(1)
101
0.099
64
0.188
Proximal
74
(62.2)
32
(50.8)
31
(49.2)
23
(54.8)
19
(45.2)
Distal
45
(37.8)
26
(68.4)
12
(31.6)
16
(72.7)
6
(27.3)
ypT category
n
p(2)
101
0.020
64
0.029
ypT0
13
(10.9)
3
(100.0)
0
(0.0)
ypT1a/T1b
19
(16.0)
13
(76.5)
4
(23.5)
1
(50.0)
1
(50.0)
ypT2
15
(12.6)
10
(66.7)
5
(33.3)
9
(81.8)
2
(18.2)
ypT3
63
(52.9)
32
(53.3)
28
(46.7)
24
(57.1)
18
(42.9)
ypT4a/T4b
9
(7.6)
3
(33.3)
6
(66.7)
2
(33.3)
4
(66.7)
ypN category
n
p(2)
101
0.015
64
0.004#
ypN0
44
(37.0)
22
(71.0)
9
(29.0)
ypN1
27
(22.7)
17
(68.0)
8
(32.0)
18
(81.8)
4
(18.2)
ypN2
25
(21.0)
9
(39.1)
14
(60.9)
13
(61.9)
8
(38.1)
ypN3
23
(19.3)
10
(45.5)
12
(54.5)
8
(38.1)
13
(61.9)
M category
n
p(1)
101
0.797
64
1.000
M0
98
(82.4)
47
(56.6)
36
(43.4)
32
(61.5)
20
(38.5)
M1
21
(17.6)
11
(61.1)
7
(38.9)
7
(58.3)
5
(41.7)
UICC stage
n
p(2)
101
0.283
64
0.099
0/0/N+
12
(10.1)
2
(100.0)
0
(0.0)
IA/IB
19
(16.0)
13
(72.2)
5
(27.8)
0
(0)
0
(0)
IIA/IIB
21
(17.6)
13
(61.9)
8
(38.1)
9
(90.0)
1
(10.0)
IIIA/IIIB/IIIC
46
(38.7)
21
(47.7)
23
(52.3)
21
(52.5)
19
(47.5)
IV
21
(17.6)
11
(61.1)
7
(38.9)
7
(58.3)
5
(41.7)
(b)
Valid
Primary resected tumor
Lymph node metastasis
LGR5 score 0-6
MIST1 score 0-6
Low (0-4)
High (5-6)
Negative (0)
Positive (2-6)
n
(%)
n
(%)
n
(%)
n
(%)
n
(%)
L category
n
p(1)
101
0.002#
64
0.011
L0
84
(70.6)
47
(68.1)
22
(31.9)
27
(75.0)
9
(25.0)
L1
35
(29.4)
11
(34.4)
21
(65.6)
12
(42.9)
16
(57.1)
V category
n
p(1)
101
0.010
64
0.100
V0
111
(93.3)
57
(61.3)
36
(38.7)
37
(64.9)
20
(35.1)
V1
8
(6.7)
1
(12.5)
7
(87.5)
2
(28.6)
5
(71.4)
Pn category
n
p(1)
101
0.229
64
0.009
Pn0
95
(79.8)
48
(60.8)
31
(39.2)
33
(71.7)
13
(28.3)
Pn1
24
(20.2)
10
(45.5)
12
(54.5)
6
(33.3)
12
(66.7)
R status
n
p(1)
101
0.861
64
0.108
R0
106
(89.1)
51
(58.0)
37
(42.0)
35
(66.0)
18
(34.0)
R1
12
(10.1)
6
(50.0)
6
(50.0)
4
(40.0)
6
(60.0)
RX
1
(0.8)
1
(100.0)
0
(0.0)
0
(0.0)
1
(100.0)
Overall survival
n
p(3)
97
0.679
60
<0.001#
Total/events/censored
115/67/48
56/37/19
41/25/16
36/26/10
24/19/5
Median survival
26.6±2.7
22.4±6.6
22.8±8.6
24.3±3.9
7.0±1.4
95% C.I.
21.4-31.8
9.5-35.3
6.0-39.6
16.6-32.0
4.3-9.8
Tumor-specific survival
n
p(3)
97
0.953
60
0.001#
Total/events/censored
115/55/60
56/32/24
41/19/22
36/24/12
24/16/8
Median survival
29.5±2.8
26.7±4.3
32.0±8.9
24.6±3.0
7.6±0.4
95% C.I.
24.0-34.9
18.3-35.2
14.5-49.6
18.8-30.4
6.7-8.4
(1)Fisher’s exact test; (2)Kendall’s tau test; (3)log-rank test; #significant after multiple testing.


### 3.1. Study Cohort

The study cohort consisted of 119 patients. Primary tumors could be evaluated in 118 cases, pretherapeutic biopsies in 25, lymph node metastases and/or lymph nodes with features of tumor regression in 79, and distant metastases in 14. Thirteen patients (10.9%) showed complete tumor regression of the primary tumor (Becker regression score 1a), of which three still had viable tumor cells in lymph node metastases suitable for histological classification. 25 cases (21%) contained less than 10% of vital tumor residuals in the primary tumor tissue (Becker regression score 1b). 19 (16%) contained 10-50% of vital tumor residuals (Becker regression score 2) and 62 (52.1%) showed more than 50% of vital tumor residuals (Becker regression score 3). 25 patients (21%) had a diffuse, 52 (43.7%) an intestinal, 18 (15.1%) a mixed, and 14 (11.8%) an unclassifiable type of GC according to Laurén [49].


### 3.2. LGR5, FZD7, TROY, and MIST1 Expression in Pretherapeutic Biopsies and Neoadjuvantly Treated Tumor Tissue

#### 3.2.1. LGR5 (Figure1)

Figure 1
LGR5 expression in neoadjuvant-/perioperative-treated primary tumors. Ascending intensity of LGR5 expression in tumor cells (a–d). LGR5 is also expressed in desmoplastic stroma (e), in myocytes (f), in healthy mucosa cells (g), in endothelial cells (h), and in fat cell membranes (i). Original magnifications: 400-fold.
(a)
(b)
(c)
(d)
(e)
(f)
(g)
(h)
(i)The tumor cells of 88 (87.1%, validn=101) primary GCs, 54 (77.1%, valid n=70) lymph node metastases, 10 (100%, valid n=10) distant metastases, and 21 (87.5%, valid n=24) pretherapeutic biopsies showed a cytoplasmic expression of LGR5. LGR5 was also found in endothelial cells, nonneoplastic epithelium, stroma cells, myocytes, and fat cells as described by Simon et al. [16].In the primary tumor, LGR5 was found in the tumor center in 72 (71.3%; validn=101) and at the invasion front in 71 (70.3%) primary GCs. The tumor surface could only be evaluated in 81 cases, of which 57 (70.4%) expressed LGR5. While the tumor center and invasion front correlated with each other (p<0.001), there was no correlation between the tumor surface and tumor center (p=0.061) or tumor surface and invasion front (p=0.032, not significant after multiple testing; data not shown).


#### 3.2.2. MIST1 (Figure2)

Figure 2
MIST1 expression in neoadjuvant-/perioperative-treated primary tumors. Ascending intensity of MIST1 expression in tumor cells (a–d). MIST1 is also expressed in inflammatory cells (e) and in cells of the healthy mucosa (f). Original magnifications: 400-fold.
(a)
(b)
(c)
(d)
(e)
(f)Nuclear immunostaining of MIST1 was found in tumor cells of 55 (53.9%; validn=102) primary GCs, 25 (39.1%; valid n=64) lymph node metastasis, 4 (44.4%; valid n=9) distant metastases, and 6 (26.1%; valid n=23) pretherapeutic biopsies.Tumor cells expressed MIST1 in the tumor center of 51 (50.0%, validn=102) and at the invasion front of 43 (42.2%, valid n=102) GCs. The tumor surface could only be assessed in 80 cases, of which 29 (36.3%) showed MIST1-positive tumor cells. The expression of MIST1 at the tumor surface, tumor center, and invasion front correlated significantly which each other (p<0.001 each; data not shown).MIST1 was also expressed by inflammatory cells, as previously reported by Lennerz et al. [54], and by epithelial cells of the nonneoplastic mucosa.


#### 3.2.3. FZD7 (Figure3)

Figure 3
FZD7 expression in neoadjuvant-/perioperative-treated primary tumors. Ascending intensity of FZD7 expression in tumor cells (a–d). FZD7 is also expressed in myocytes (e), in cells of the healthy mucosa (f), in inflammatory cells (g), and in metaplastic cells (h). Original magnifications: 400-fold.
(a)
(b)
(c)
(d)
(e)
(f)
(g)
(h)FZD7 was expressed in tumor cells of 73 (73%; validn=100) primary GCs, 34 (54%; valid n=63) lymph node metastases, 4 (50%; valid n=8) distant metastases, and 10 (45.5%; valid n=22) pretherapeutic biopsies. Cytoplasmic staining was observed in 67 (67%; valid n=100) primary GCs, 34 (54%; valid n=63) lymph node metastases, 4 (50%; valid n=8) distant metastases, and 9 (40.9%; valid n=22) pretherapeutic biopsies. Cell-membrane staining was present in 5 (5%; valid n=100) primary GCs, 1 (1.6%; valid n=63) lymph node metastasis, and 1 (4.5%; valid n=22) pretherapeutic biopsy. Membranous staining was not found in any distant metastasis. In addition, 7 (7%; valid n=100) primary tumors; none of the lymph node metastases, or distant metastases; and 2 (9.1%; valid n=22) pretherapeutic biopsies expressed FZD7 nuclear membrane-bound.Tumor cells expressed FZD7 in the tumor center of 58 (58%; validn=100) and at the invasion front of 48 (48%; valid n=100) primary GCs. The tumor surface was assessable in 74 cases, of which 43 (58.1%) expressed FZD7. The expression of FZD7 at the tumor surface, tumor center, and invasion front correlated significantly with each other (surface vs. center: p=0.004; surface vs. invasion front: p<0.001; center vs. invasion front: p<0.001; data not shown).An expression of FZD7 was also observed in inflammatory cells, endothelial cells, intestinal metaplasia, and cells of the nonneoplastic mucosa.


#### 3.2.4. TROY (Figure4)

Figure 4
TROY expression in neoadjuvant-/perioperative-treated primary tumors. Expression of TROY in tumor cells of a lymph node (a) and a distant metastasis (b). TROY is also expressed in desmoplastic stromal cells (c) and in myocytes (d). Original magnifications: 400-fold.
(a)
(b)
(c)
(d)Assessment of TROY immunostaining was cumbersome. Only 1 of 60 valid lymph node metastases (1.7%) and 1 of 14 distant metastases (7.1%), but none of the 100 valid primary tumors and none of the 21 valid pretherapeutic biopsies, expressed TROY in tumor cells. However, TROY was found in myocytes and stroma cells, as already reported by Wilhelm et al. [37]. Nearly all tissue sections, 97% (97 out of 100) of the primary tumor, 90.5% (19 out of 21) of pretherapeutic biopsies, 95% (57 out of 60) of lymph node metastasis, and 100% of distant metastases had a TROY-immunoreactive stroma. The maximum percentage of TROY-positive tumor cells was 5%. Hence, TROY was excluded from further analysis of tumor cells.


### 3.3. Immunoreactivity Score

The distribution patterns of each stem cell marker in the tumor cells of the primary GCs according to the intensity of immunostaining (category A) and with regard to the percentage of immunopositive cells (category B) were summarized (Supplementary FileS2). For LGR5 and FZD7, the percentage of positive tumor cells varied between 0 and 100%, while the percentage of MIST1-positive tumor cells varied between 0 and 75%. The addition of categories A and B resulted in an IRS ranging from 0 to 6 for each individual case and marker. For statistical analyses, we dichotomized each stem cell marker at the median IRS, i.e. for primary tumor, IRS≤4 vs. ≥5 (LGR5), IRS≤3 vs. ≥4 (FZD7), and IRS=0 vs. ≥2 (MIST1) (Supplementary File S3). Following dichotomization, no significant correlation was found between the expression of any of the markers in the primary GCs (LGR5 vs. MIST1: p=0.687; LGR5 vs. FZD7: p=0.840; and MIST1 vs. FZD7: p=0.310).


### 3.4. Correlation with Therapy Response

Next, we correlated the expression of the different stem cell markers with therapy response according to the Becker regression grade and the percentage of vital tumor cells in the tumor bed.Interestingly, the expression of LGR5 in the primary GCs correlated significantly with the Becker regression grade as well as with the percentage of vital tumor cells (p<0.001 each; Table 2; Supplementary File 4). No correlation was found between the expression of LGR5 in tumor cells of pretherapeutic biopsies and therapy response (Supplementary File S5).Table 2
Correlation of LGR5 and MIST1 expression in primary resected gastric cancer and pretherapeutic biopsies, respectively, with tumor regression.
Valid
Primary resected tumor
Pretherapeutic biopsy
LGR5 score 0-6
MIST1 score 0-6
Low (0-4)
High (5-6)
Negative (0)
Positive (2-6)
n
(%)
n
(%)
n
(%)
n
(%)
n
(%)
Vital tumor residuals
n
p(1)
101
<0.001#
23
0.048
<Median (0-54%)
59
(49.6)
34
(79.1)
9
(20.9)
9
(100.0)
0
(0.0)
≥Median (55-100%)
60
(50.4)
24
(41.4)
34
(58.6)
8
(57.1)
6
(42.9)
Vital tumor residuals
n
p(2)
101
<0.001#
23
0.012
Quartile 1 (0-4%)
23
(19.3)
8
(100.0)
0
(0.0)
3
(100.0)
0
(0.0)
Quartile 2 (5-54%)
36
(30.3)
26
(74.3)
9
(25.7)
6
(100.0)
0
(0.0)
Quartile 3 (55-89%)
29
(24.4)
14
(50.0)
14
(50.0)
4
(80.0)
1
(20.0)
Quartile 4 (90-100%)
31
(26.1)
10
(33.3)
20
(66.7)
4
(44.4)
5
(55.6)
Becker regression score
n
p(2)
101
<0.001#
23
0.046
1a
13
(10.9)
2
(100.0)
0
(0.0)
1b
25
(21.0)
19
(82.6)
4
(17.4)
2
(100.0)
0
(0.0)
2
19
(16.0)
13
(72.2)
5
(27.8)
5
(100.0)
0
(0.0)
3
62
(52.1)
26
(43.3)
34
(56.7)
8
(57.1)
6
(42.9)
(1)Fisher’s exact test; (2)Kendall’s tau test; #significant after multiple testing.The expression of MIST1 in tumor cells of the primary tumor did not correlate with the response to the treatment (Supplementary FileS5). Interestingly, MIST1 expression in the pretherapeutic biopsy specimens correlated with the Becker regression score (p=0.046) and with the percentage of tumor residuals divided by the median (p=0.048) or divided into quartiles (p=0.012). However, these associations lost significance after multiple testing (Table 2; Supplementary File 4).No correlation was found between FZD7 expression and response to therapy (Supplementary FileS5).


### 3.5. Correlation with Clinicopathological Patient Characteristics

LGR5 expression in tumor cells of primary GCs correlated only with lymph vessel invasion (L category,p=0.002; Table 1). Also, the expression of LGR5 in lymph node metastases was associated with lymph vessel invasion (p=0.001) (Supplementary File S6). No correlation was found between the LGR5 expression in pretherapeutic biopsies and any clinicopathological patient characteristic (Supplementary File S6).MIST1 expression in primary GCs and pretherapeutic biopsies did not correlate with any clinicopathological patient characteristic (Supplementary FileS6). To the contrary, MIST1 expression in lymph node metastases correlated significantly with the number of lymph node metastases (p=0.004): a strong expression of MIST1 in lymph node metastases was associated with a higher N category (Table 1).FZD7 expression did not correlate with any of the characteristics, either in the primary tumors or in the pretherapeutic biopsies or in lymph node metastases (Supplementary FileS6).


### 3.6. Correlation between the Expression in Primary Tumors and the Expression in Lymph Node Metastases/Distant Metastases

The expression of the three stem cell markers in primary GCs revealed a significant association with their expression in lymph node metastasis (LGR5:p=0.001; MIST1: p=0.002; and FZD7: p=0.004; data not shown). However, there was also a large group of discordant cases that did not match the score of primary tumors and the lymph node metastasis. In the small number of evaluable distant metastases, no marker showed a significant correlation between the expression in the primary GCs and the expression in distant metastasis (LGR5: p=0.133; MIST1: p=0.167; and FZD7: p=0.467; data not shown).


### 3.7. Comparison of Pretherapeutic and Posttherapeutic Expression

There was no association between the expression in pretherapeutic biopsies and the expression in neoadjuvant/perioperative treated primary tumors for any marker (LGR5:p=0.087; MIST1: p=0.642; and FZD7: p=0.637; Supplementary File 7).


### 3.8. Prognostic Significance

Patient prognosis significantly depended on several clinicopathological parameters (Supplementary FileS8) as well as on the MIST1 expression in tumor cells of the lymph node metastasis (Figure 5; Table 1). Patients with MIST1 expression in metastatic tumor cells showed significantly worse overall (p<0.001) and tumor-specific survival (p=0.001).Figure 5
Survival analysis of MIST1 using Kaplan-Meier plots. Kaplan-Meier curves depicting overall survival of the validation cohort according to the MIST1 expression in the primary tumor (a) and lymph node metastasis (c) as well as tumor-specific survival of the validation cohort according to the MIST1 expression in the primary tumor (b) and lymph node metastasis (d).
(a)
(b)
(c)
(d)For LGR5, no relationship with patient survival was found (Table1, Supplementary File S6 and S9). The survival analysis was also analyzed separately for each histoanatomical location, i.e., tumor surface, tumor center, and invasion front. However, LGR5 expression did not correlate with patient survival (data not shown). Patient prognosis also did not correlate with FZD7 (Supplementary File S10).


## 3.1. Study Cohort

The study cohort consisted of 119 patients. Primary tumors could be evaluated in 118 cases, pretherapeutic biopsies in 25, lymph node metastases and/or lymph nodes with features of tumor regression in 79, and distant metastases in 14. Thirteen patients (10.9%) showed complete tumor regression of the primary tumor (Becker regression score 1a), of which three still had viable tumor cells in lymph node metastases suitable for histological classification. 25 cases (21%) contained less than 10% of vital tumor residuals in the primary tumor tissue (Becker regression score 1b). 19 (16%) contained 10-50% of vital tumor residuals (Becker regression score 2) and 62 (52.1%) showed more than 50% of vital tumor residuals (Becker regression score 3). 25 patients (21%) had a diffuse, 52 (43.7%) an intestinal, 18 (15.1%) a mixed, and 14 (11.8%) an unclassifiable type of GC according to Laurén [49].


## 3.2. LGR5, FZD7, TROY, and MIST1 Expression in Pretherapeutic Biopsies and Neoadjuvantly Treated Tumor Tissue

### 3.2.1. LGR5 (Figure1)

Figure 1
LGR5 expression in neoadjuvant-/perioperative-treated primary tumors. Ascending intensity of LGR5 expression in tumor cells (a–d). LGR5 is also expressed in desmoplastic stroma (e), in myocytes (f), in healthy mucosa cells (g), in endothelial cells (h), and in fat cell membranes (i). Original magnifications: 400-fold.
(a)
(b)
(c)
(d)
(e)
(f)
(g)
(h)
(i)The tumor cells of 88 (87.1%, validn=101) primary GCs, 54 (77.1%, valid n=70) lymph node metastases, 10 (100%, valid n=10) distant metastases, and 21 (87.5%, valid n=24) pretherapeutic biopsies showed a cytoplasmic expression of LGR5. LGR5 was also found in endothelial cells, nonneoplastic epithelium, stroma cells, myocytes, and fat cells as described by Simon et al. [16].In the primary tumor, LGR5 was found in the tumor center in 72 (71.3%; validn=101) and at the invasion front in 71 (70.3%) primary GCs. The tumor surface could only be evaluated in 81 cases, of which 57 (70.4%) expressed LGR5. While the tumor center and invasion front correlated with each other (p<0.001), there was no correlation between the tumor surface and tumor center (p=0.061) or tumor surface and invasion front (p=0.032, not significant after multiple testing; data not shown).


### 3.2.2. MIST1 (Figure2)

Figure 2
MIST1 expression in neoadjuvant-/perioperative-treated primary tumors. Ascending intensity of MIST1 expression in tumor cells (a–d). MIST1 is also expressed in inflammatory cells (e) and in cells of the healthy mucosa (f). Original magnifications: 400-fold.
(a)
(b)
(c)
(d)
(e)
(f)Nuclear immunostaining of MIST1 was found in tumor cells of 55 (53.9%; validn=102) primary GCs, 25 (39.1%; valid n=64) lymph node metastasis, 4 (44.4%; valid n=9) distant metastases, and 6 (26.1%; valid n=23) pretherapeutic biopsies.Tumor cells expressed MIST1 in the tumor center of 51 (50.0%, validn=102) and at the invasion front of 43 (42.2%, valid n=102) GCs. The tumor surface could only be assessed in 80 cases, of which 29 (36.3%) showed MIST1-positive tumor cells. The expression of MIST1 at the tumor surface, tumor center, and invasion front correlated significantly which each other (p<0.001 each; data not shown).MIST1 was also expressed by inflammatory cells, as previously reported by Lennerz et al. [54], and by epithelial cells of the nonneoplastic mucosa.


### 3.2.3. FZD7 (Figure3)

Figure 3
FZD7 expression in neoadjuvant-/perioperative-treated primary tumors. Ascending intensity of FZD7 expression in tumor cells (a–d). FZD7 is also expressed in myocytes (e), in cells of the healthy mucosa (f), in inflammatory cells (g), and in metaplastic cells (h). Original magnifications: 400-fold.
(a)
(b)
(c)
(d)
(e)
(f)
(g)
(h)FZD7 was expressed in tumor cells of 73 (73%; validn=100) primary GCs, 34 (54%; valid n=63) lymph node metastases, 4 (50%; valid n=8) distant metastases, and 10 (45.5%; valid n=22) pretherapeutic biopsies. Cytoplasmic staining was observed in 67 (67%; valid n=100) primary GCs, 34 (54%; valid n=63) lymph node metastases, 4 (50%; valid n=8) distant metastases, and 9 (40.9%; valid n=22) pretherapeutic biopsies. Cell-membrane staining was present in 5 (5%; valid n=100) primary GCs, 1 (1.6%; valid n=63) lymph node metastasis, and 1 (4.5%; valid n=22) pretherapeutic biopsy. Membranous staining was not found in any distant metastasis. In addition, 7 (7%; valid n=100) primary tumors; none of the lymph node metastases, or distant metastases; and 2 (9.1%; valid n=22) pretherapeutic biopsies expressed FZD7 nuclear membrane-bound.Tumor cells expressed FZD7 in the tumor center of 58 (58%; validn=100) and at the invasion front of 48 (48%; valid n=100) primary GCs. The tumor surface was assessable in 74 cases, of which 43 (58.1%) expressed FZD7. The expression of FZD7 at the tumor surface, tumor center, and invasion front correlated significantly with each other (surface vs. center: p=0.004; surface vs. invasion front: p<0.001; center vs. invasion front: p<0.001; data not shown).An expression of FZD7 was also observed in inflammatory cells, endothelial cells, intestinal metaplasia, and cells of the nonneoplastic mucosa.


### 3.2.4. TROY (Figure4)

Figure 4
TROY expression in neoadjuvant-/perioperative-treated primary tumors. Expression of TROY in tumor cells of a lymph node (a) and a distant metastasis (b). TROY is also expressed in desmoplastic stromal cells (c) and in myocytes (d). Original magnifications: 400-fold.
(a)
(b)
(c)
(d)Assessment of TROY immunostaining was cumbersome. Only 1 of 60 valid lymph node metastases (1.7%) and 1 of 14 distant metastases (7.1%), but none of the 100 valid primary tumors and none of the 21 valid pretherapeutic biopsies, expressed TROY in tumor cells. However, TROY was found in myocytes and stroma cells, as already reported by Wilhelm et al. [37]. Nearly all tissue sections, 97% (97 out of 100) of the primary tumor, 90.5% (19 out of 21) of pretherapeutic biopsies, 95% (57 out of 60) of lymph node metastasis, and 100% of distant metastases had a TROY-immunoreactive stroma. The maximum percentage of TROY-positive tumor cells was 5%. Hence, TROY was excluded from further analysis of tumor cells.


## 3.2.1. LGR5 (Figure1)

Figure 1
LGR5 expression in neoadjuvant-/perioperative-treated primary tumors. Ascending intensity of LGR5 expression in tumor cells (a–d). LGR5 is also expressed in desmoplastic stroma (e), in myocytes (f), in healthy mucosa cells (g), in endothelial cells (h), and in fat cell membranes (i). Original magnifications: 400-fold.
(a)
(b)
(c)
(d)
(e)
(f)
(g)
(h)
(i)The tumor cells of 88 (87.1%, validn=101) primary GCs, 54 (77.1%, valid n=70) lymph node metastases, 10 (100%, valid n=10) distant metastases, and 21 (87.5%, valid n=24) pretherapeutic biopsies showed a cytoplasmic expression of LGR5. LGR5 was also found in endothelial cells, nonneoplastic epithelium, stroma cells, myocytes, and fat cells as described by Simon et al. [16].In the primary tumor, LGR5 was found in the tumor center in 72 (71.3%; validn=101) and at the invasion front in 71 (70.3%) primary GCs. The tumor surface could only be evaluated in 81 cases, of which 57 (70.4%) expressed LGR5. While the tumor center and invasion front correlated with each other (p<0.001), there was no correlation between the tumor surface and tumor center (p=0.061) or tumor surface and invasion front (p=0.032, not significant after multiple testing; data not shown).


## 3.2.2. MIST1 (Figure2)

Figure 2
MIST1 expression in neoadjuvant-/perioperative-treated primary tumors. Ascending intensity of MIST1 expression in tumor cells (a–d). MIST1 is also expressed in inflammatory cells (e) and in cells of the healthy mucosa (f). Original magnifications: 400-fold.
(a)
(b)
(c)
(d)
(e)
(f)Nuclear immunostaining of MIST1 was found in tumor cells of 55 (53.9%; validn=102) primary GCs, 25 (39.1%; valid n=64) lymph node metastasis, 4 (44.4%; valid n=9) distant metastases, and 6 (26.1%; valid n=23) pretherapeutic biopsies.Tumor cells expressed MIST1 in the tumor center of 51 (50.0%, validn=102) and at the invasion front of 43 (42.2%, valid n=102) GCs. The tumor surface could only be assessed in 80 cases, of which 29 (36.3%) showed MIST1-positive tumor cells. The expression of MIST1 at the tumor surface, tumor center, and invasion front correlated significantly which each other (p<0.001 each; data not shown).MIST1 was also expressed by inflammatory cells, as previously reported by Lennerz et al. [54], and by epithelial cells of the nonneoplastic mucosa.


## 3.2.3. FZD7 (Figure3)

Figure 3
FZD7 expression in neoadjuvant-/perioperative-treated primary tumors. Ascending intensity of FZD7 expression in tumor cells (a–d). FZD7 is also expressed in myocytes (e), in cells of the healthy mucosa (f), in inflammatory cells (g), and in metaplastic cells (h). Original magnifications: 400-fold.
(a)
(b)
(c)
(d)
(e)
(f)
(g)
(h)FZD7 was expressed in tumor cells of 73 (73%; validn=100) primary GCs, 34 (54%; valid n=63) lymph node metastases, 4 (50%; valid n=8) distant metastases, and 10 (45.5%; valid n=22) pretherapeutic biopsies. Cytoplasmic staining was observed in 67 (67%; valid n=100) primary GCs, 34 (54%; valid n=63) lymph node metastases, 4 (50%; valid n=8) distant metastases, and 9 (40.9%; valid n=22) pretherapeutic biopsies. Cell-membrane staining was present in 5 (5%; valid n=100) primary GCs, 1 (1.6%; valid n=63) lymph node metastasis, and 1 (4.5%; valid n=22) pretherapeutic biopsy. Membranous staining was not found in any distant metastasis. In addition, 7 (7%; valid n=100) primary tumors; none of the lymph node metastases, or distant metastases; and 2 (9.1%; valid n=22) pretherapeutic biopsies expressed FZD7 nuclear membrane-bound.Tumor cells expressed FZD7 in the tumor center of 58 (58%; validn=100) and at the invasion front of 48 (48%; valid n=100) primary GCs. The tumor surface was assessable in 74 cases, of which 43 (58.1%) expressed FZD7. The expression of FZD7 at the tumor surface, tumor center, and invasion front correlated significantly with each other (surface vs. center: p=0.004; surface vs. invasion front: p<0.001; center vs. invasion front: p<0.001; data not shown).An expression of FZD7 was also observed in inflammatory cells, endothelial cells, intestinal metaplasia, and cells of the nonneoplastic mucosa.


## 3.2.4. TROY (Figure4)

Figure 4
TROY expression in neoadjuvant-/perioperative-treated primary tumors. Expression of TROY in tumor cells of a lymph node (a) and a distant metastasis (b). TROY is also expressed in desmoplastic stromal cells (c) and in myocytes (d). Original magnifications: 400-fold.
(a)
(b)
(c)
(d)Assessment of TROY immunostaining was cumbersome. Only 1 of 60 valid lymph node metastases (1.7%) and 1 of 14 distant metastases (7.1%), but none of the 100 valid primary tumors and none of the 21 valid pretherapeutic biopsies, expressed TROY in tumor cells. However, TROY was found in myocytes and stroma cells, as already reported by Wilhelm et al. [37]. Nearly all tissue sections, 97% (97 out of 100) of the primary tumor, 90.5% (19 out of 21) of pretherapeutic biopsies, 95% (57 out of 60) of lymph node metastasis, and 100% of distant metastases had a TROY-immunoreactive stroma. The maximum percentage of TROY-positive tumor cells was 5%. Hence, TROY was excluded from further analysis of tumor cells.


## 3.3. Immunoreactivity Score

The distribution patterns of each stem cell marker in the tumor cells of the primary GCs according to the intensity of immunostaining (category A) and with regard to the percentage of immunopositive cells (category B) were summarized (Supplementary FileS2). For LGR5 and FZD7, the percentage of positive tumor cells varied between 0 and 100%, while the percentage of MIST1-positive tumor cells varied between 0 and 75%. The addition of categories A and B resulted in an IRS ranging from 0 to 6 for each individual case and marker. For statistical analyses, we dichotomized each stem cell marker at the median IRS, i.e. for primary tumor, IRS≤4 vs. ≥5 (LGR5), IRS≤3 vs. ≥4 (FZD7), and IRS=0 vs. ≥2 (MIST1) (Supplementary File S3). Following dichotomization, no significant correlation was found between the expression of any of the markers in the primary GCs (LGR5 vs. MIST1: p=0.687; LGR5 vs. FZD7: p=0.840; and MIST1 vs. FZD7: p=0.310).


## 3.4. Correlation with Therapy Response

Next, we correlated the expression of the different stem cell markers with therapy response according to the Becker regression grade and the percentage of vital tumor cells in the tumor bed.Interestingly, the expression of LGR5 in the primary GCs correlated significantly with the Becker regression grade as well as with the percentage of vital tumor cells (p<0.001 each; Table 2; Supplementary File 4). No correlation was found between the expression of LGR5 in tumor cells of pretherapeutic biopsies and therapy response (Supplementary File S5).Table 2
Correlation of LGR5 and MIST1 expression in primary resected gastric cancer and pretherapeutic biopsies, respectively, with tumor regression.
Valid
Primary resected tumor
Pretherapeutic biopsy
LGR5 score 0-6
MIST1 score 0-6
Low (0-4)
High (5-6)
Negative (0)
Positive (2-6)
n
(%)
n
(%)
n
(%)
n
(%)
n
(%)
Vital tumor residuals
n
p(1)
101
<0.001#
23
0.048
<Median (0-54%)
59
(49.6)
34
(79.1)
9
(20.9)
9
(100.0)
0
(0.0)
≥Median (55-100%)
60
(50.4)
24
(41.4)
34
(58.6)
8
(57.1)
6
(42.9)
Vital tumor residuals
n
p(2)
101
<0.001#
23
0.012
Quartile 1 (0-4%)
23
(19.3)
8
(100.0)
0
(0.0)
3
(100.0)
0
(0.0)
Quartile 2 (5-54%)
36
(30.3)
26
(74.3)
9
(25.7)
6
(100.0)
0
(0.0)
Quartile 3 (55-89%)
29
(24.4)
14
(50.0)
14
(50.0)
4
(80.0)
1
(20.0)
Quartile 4 (90-100%)
31
(26.1)
10
(33.3)
20
(66.7)
4
(44.4)
5
(55.6)
Becker regression score
n
p(2)
101
<0.001#
23
0.046
1a
13
(10.9)
2
(100.0)
0
(0.0)
1b
25
(21.0)
19
(82.6)
4
(17.4)
2
(100.0)
0
(0.0)
2
19
(16.0)
13
(72.2)
5
(27.8)
5
(100.0)
0
(0.0)
3
62
(52.1)
26
(43.3)
34
(56.7)
8
(57.1)
6
(42.9)
(1)Fisher’s exact test; (2)Kendall’s tau test; #significant after multiple testing.The expression of MIST1 in tumor cells of the primary tumor did not correlate with the response to the treatment (Supplementary FileS5). Interestingly, MIST1 expression in the pretherapeutic biopsy specimens correlated with the Becker regression score (p=0.046) and with the percentage of tumor residuals divided by the median (p=0.048) or divided into quartiles (p=0.012). However, these associations lost significance after multiple testing (Table 2; Supplementary File 4).No correlation was found between FZD7 expression and response to therapy (Supplementary FileS5).


## 3.5. Correlation with Clinicopathological Patient Characteristics

LGR5 expression in tumor cells of primary GCs correlated only with lymph vessel invasion (L category,p=0.002; Table 1). Also, the expression of LGR5 in lymph node metastases was associated with lymph vessel invasion (p=0.001) (Supplementary File S6). No correlation was found between the LGR5 expression in pretherapeutic biopsies and any clinicopathological patient characteristic (Supplementary File S6).MIST1 expression in primary GCs and pretherapeutic biopsies did not correlate with any clinicopathological patient characteristic (Supplementary FileS6). To the contrary, MIST1 expression in lymph node metastases correlated significantly with the number of lymph node metastases (p=0.004): a strong expression of MIST1 in lymph node metastases was associated with a higher N category (Table 1).FZD7 expression did not correlate with any of the characteristics, either in the primary tumors or in the pretherapeutic biopsies or in lymph node metastases (Supplementary FileS6).


## 3.6. Correlation between the Expression in Primary Tumors and the Expression in Lymph Node Metastases/Distant Metastases

The expression of the three stem cell markers in primary GCs revealed a significant association with their expression in lymph node metastasis (LGR5:p=0.001; MIST1: p=0.002; and FZD7: p=0.004; data not shown). However, there was also a large group of discordant cases that did not match the score of primary tumors and the lymph node metastasis. In the small number of evaluable distant metastases, no marker showed a significant correlation between the expression in the primary GCs and the expression in distant metastasis (LGR5: p=0.133; MIST1: p=0.167; and FZD7: p=0.467; data not shown).


## 3.7. Comparison of Pretherapeutic and Posttherapeutic Expression

There was no association between the expression in pretherapeutic biopsies and the expression in neoadjuvant/perioperative treated primary tumors for any marker (LGR5:p=0.087; MIST1: p=0.642; and FZD7: p=0.637; Supplementary File 7).


## 3.8. Prognostic Significance

Patient prognosis significantly depended on several clinicopathological parameters (Supplementary FileS8) as well as on the MIST1 expression in tumor cells of the lymph node metastasis (Figure 5; Table 1). Patients with MIST1 expression in metastatic tumor cells showed significantly worse overall (p<0.001) and tumor-specific survival (p=0.001).Figure 5
Survival analysis of MIST1 using Kaplan-Meier plots. Kaplan-Meier curves depicting overall survival of the validation cohort according to the MIST1 expression in the primary tumor (a) and lymph node metastasis (c) as well as tumor-specific survival of the validation cohort according to the MIST1 expression in the primary tumor (b) and lymph node metastasis (d).
(a)
(b)
(c)
(d)For LGR5, no relationship with patient survival was found (Table1, Supplementary File S6 and S9). The survival analysis was also analyzed separately for each histoanatomical location, i.e., tumor surface, tumor center, and invasion front. However, LGR5 expression did not correlate with patient survival (data not shown). Patient prognosis also did not correlate with FZD7 (Supplementary File S10).


## 4. Discussion

The cancer stem cell model is considered as a putative cause of resistance to chemotherapy and disease recurrence in diverse malignant tumors, including GC. While the CSC model is now generally accepted, classification of single biomarkers such as CSC markers is cumbersome and often based on observations made in model systems, i.e., mouse or cell culture experiments. In addition, proof of their significance in clinical samples is scarce or even lacking. In our study, we aimed to fill this gap of information and studied the expression and tumor biological significance of four gastric CSC markers in a cohort of 119 patients with neoadjuvantly/perioperativley treated GCs.Our selection of four CSC markers for GC, i.e., LGR5, FZD7, MIST1, and TROY, was based on either cell culture experiments using side populations (as surrogate for CSC), lineage tracing experiments in mice, or studies on clinical samples providing evidence of a stem cell marker [13–16, 25, 26, 28, 30, 31, 37, 40–42, 46, 47, 55, 56].All four markers were detected in our cohort, albeit with variable prevalence and histoanatomical distributions. We observed a coexpression of LGR5, FZD7, and MIST1 in 41.2% of GCs and a complete lack only in 6.2% of the cases. The expression was not interrelated (i.e., between LGR5, FZD7, and MIST1) and may reflect the coexistence of different CSC phenotypes supporting the contention that cancers can harbor heterogeneous and biologically distinct populations of CSCs [57]. Wang et al. provided evidence for the metastatic potential of LGR5 cells: knockdown of LGR5 arrested tumor cell proliferation and invasion [58]. FZD7, in turn, is the predominant Wnt receptor responsible for transmitting Wnt signaling in gastric tumor cells and plays an essential role in tumorigenesis [29]. Interestingly, we could show that the expression of LGR5, FZD7, and MIST1 in the primary tumors correlated significantly with their expression in the corresponding lymph node metastases. These findings lead to the conjecture that LGR5-, FZD7-, and MIST1-positive tumor cells have metastatic potential, in line with observations made in mouse models [29, 58].With regard to LGR5- and FZD7-positive GCs, their prevalence was higher in neoadjuvantly/perioperatively treated primary tumors compared with treatment-naïve GCs, i.e., 87% vs. 50% for LGR5 [16, 17, 59] and 73% vs. 34% for FZD7 [28]. Our findings are in line with those of Xi et al., who studied the expression of LGR5 in neoadjuvantly treated GCs of a Chinese patient collective. Their number of LGR5-positive GCs reached 66% and was significantly higher compared with treatment-naïve tumors [20]. Collectively, these data support the notion that neoadjuvant/perioperative chemotherapy of GC leads to proportional increase of tumor cells expressing stem cell markers, which cannot be predicted by an analysis of pretherapeutic biopsies.The increased expression of LGR5 correlated significantly with tumor regression. While tumor regression decreases the overall tumor mass, our IRS documented percentage of tumor cells present and the intensity of immunostaining, both being independent from the total tumor mass present in a given specimen. Thus, we believe that our data support the CSC model at least for LGR5-positive tumors: neoadjuvant/perioperative chemotherapy augmented the expression of stem cell markers. To the contrary, we were unable to detect a significant correlation (after multiple testing) between tumor regression and the expression of MIST1 or FZD7, in both pretherapeutic biopsies and resected primary GCs. This could be related to the cohort size at least for MIST1, which showed an insignificant (after multiple testing) correlation with Becker regression score in pretherapeutic tumor samples. Alternatively, not all stem cell markers may respond to neoadjuvant/perioperative chemotherapy in a similar way.This is further exemplified when histoanatomical distribution is considered. While the expression of MIST and FZD7 at the tumor surface, tumor center, and invasion front was interrelated significantly, no such interrelation between different tumor compartments was found for LGR5. In addition, the expression of MIST1 in lymph node metastases correlated significantly with the number of lymph node metastases as well as overall and tumor-specific survival. No such correlation was found for MIST-positive tumor cells in the primary GC. Collectively, these data illustrate the complexity of CSC biology with regard to spatial distribution, response to therapy, and prognostic significance. Different anatomical compartments/microenvironments (e.g., primary tumor and metastatic site) may reflect different niches necessitating distinct stem cell characteristics.Our results also point towards therapeutic potentials. The combination of targeted elimination of LGR5 expressing cells and chemotherapy could improve therapeutic efficacy. In addition, inhibition of MIST1 before the onset of chemotherapy might improve response rates. Neoadjuvant treatment leads to an increased prevalence of FZD7 expression in GC making it an attractive therapeutic target after “induction” chemotherapy: Flanagan et al. could already show the therapeutic potential for FZD7, and further studies on this topic are warranted [29].Only few tumor cells expressed TROY in our cohort. We used the same antibody as Wilhelm et al. [37], who detected TROY-positive tumor cells in 51% of their treatment-naïve GCs. Thus, neoadjuvant/perioperative treatment seems to reduce the expression of TROY in tumor cells. The stroma retained the expression in nearly all cases. Wilhelm et al. had shown that TROY is significantly more commonly expressed in intestinal compared with diffuse type GC and correlates inversely with the tumor grade and the nodal spread. In the intestinal type, loss of TROY expression was also associated with a significantly worse overall survival [37]. Our findings indicate that neoadjuvant/perioperative treatment of GC is not able to restore the expression of TROY and even further reduces its expression.Summing up, our study on clinical patient samples shows that (1) GCs may coexpress independently different stem cell markers; (2) neoadjuvant/perioperative treatment of GC significantly impacts on the expression of these different stem cell markers, (3) which cannot be predicted by the analysis of pretherapeutic biopsies; and (4) their expression and tumor biological effect are heterogeneous and have to be viewed as a function of histoanatomical distribution, i.e., microenvironmental cues.



---

*Source: 8154926-2019-11-19.xml*